Hikma Pharmaceuticals Plc Building Public Trust Awards - Highly Commended (1207S)
November 27 2012 - 8:45AM
UK Regulatory
TIDMHIK
RNS Number : 1207S
Hikma Pharmaceuticals Plc
27 November 2012
PRESS RELEASE
Hikma Highly Commended - Building Public Trust Awards
London, 27 November 2012 - Hikma Pharmaceuticals PLC (LSE: HIK)
(NASDAQ Dubai: HIK) ("Hikma"), the fast growing multinational
pharmaceutical group, is very pleased to announce that it has been
"Highly Commended" for its remuneration disclosure in the 2011
annual report and accounts by the Building Public Trust Awards.
The judges commented:
"Hikma's report was differentiated from others by its unusual
design and eye-catching layout. The report includes a number of
interesting features, including a consistent approach to explain
elements of remuneration by reference to desired and actual
benchmarks, together with detailed disclosure of the total
compensation paid to all directors for the year and the current
performance of the outstanding LTIP awards."
The judges were looking for disclosure of directors'
remuneration that met three key criteria:
-- A manifest commitment by the remuneration committee to best
practice reporting;
-- Clear communication of how incentive plans drive the right
behaviours in the executive team through alignment with business
strategy and the interests of stakeholders; and
-- Adoption of the changes foreshadowed in the consultation
----- ENDS -----
Enquiries
Hikma Pharmaceuticals PLC
Peter Speirs, Company Secretary +44 (0)20 7399 2772
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational
pharmaceutical group focused on developing, manufacturing and
marketing a broad range of both branded and non--branded generic
and in--licensed products. Hikma's operations are conducted through
three businesses: "Branded", "Injectables" and "Generics" based
principally in the Middle East and North Africa ("MENA") region,
where it is a market leader, the United States and Europe. In 2011,
Hikma achieved revenue of $918.0 million and profit attributable to
shareholders of $80.1 million.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCDMMZMFNZGZZM
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024